Actively Recruiting
Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients
Led by The University of Hong Kong · Updated on 2024-12-16
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
T
The University of Hong Kong
Lead Sponsor
T
The Hong Kong Society of Nephrology
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying advanced cirrhosis patients to evaluate novel plasma and urinary biomarkers that may predict the development of hepatorenal syndrome. The study compares patients who have developed hepatorenal syndrome with those who have not, aiming to understand how these biomarkers relate to the condition. It is an observational study sponsored by The University of Hong Kong. The biomarkers being monitored include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1, and urinary LFABP. These biomarkers will be measured and compared between patients with and without hepatorenal syndrome to identify potential indicators of the syndrome's occurrence. Participants will be adults aged 18 to 90 with advanced cirrhosis referred for liver transplantation. Researchers will observe and collect biomarker data and monitor the development of hepatorenal syndrome over 12 weeks, with secondary outcomes including mortality and chronic renal impairment over 6 months. The study involves no treatment interventions, focusing on biomarker assessment and patient outcomes during the observation period.
CONDITIONS
Brief Title
Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation
- Willing to give informed consent
You will not qualify if you...
- Patients with co-existing renal diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 weeks
Participants are monitored to assess plasma and urinary biomarkers to predict the development of hepatorenal syndrome.
Visits to collect plasma and urinary biomarker samples over 12 weeks
Duration - 6 months
Participants are followed for mortality and chronic renal impairment outcomes.
Follow-up visits for up to 6 months
Trial Site Locations
Total: 1 location
1
Queen Mary Hospital, Hong Kong
Hong Kong, Hong Kong
Actively Recruiting
Research Team
D
Desmond Yap, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here